Elevated serum trimethylamine N-oxide (TMAO) and trimethyllysine in patients with amyotrophic lateral sclerosis (ALS): An exploratory case–control study | Synapse
March 3, 2026Open Access
Elevated serum trimethylamine N-oxide (TMAO) and trimethyllysine in patients with amyotrophic lateral sclerosis (ALS): An exploratory case–control study
Key Points
Elevated levels of trimethylamine N-oxide and trimethyllysine were observed in patients with amyotrophic lateral sclerosis.
The study recorded significantly higher serum TMAO and trimethyllysine levels in ALS patients compared to controls.
Case-control analysis allowed for the identification of these biomarkers linked to the disease progression of ALS.
This finding highlights the potential role of these biomarkers in understanding ALS mechanisms and progression.